The purpose of this study is to evaluate how BMS955176 affects pharmacokinetics (PK) of Dolutegravir (DTG) and also how DTG administration affects the PK of BMS955176
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
14
Dolutegravir
BMS955176
GSK Investigational Site
Austin, Texas, United States
Maximum observed plasma concentration (Cmax) for DTG
Time frame: Days 1 to 5 and days 15 to 21
Area under the concentration-time curve in 1 dosing interval AUC (tau) for DTG
Time frame: Days 1 to 5 and days 15 to 21
Maximum observed plasma concentration (Cmax) for BMS-955176
Time frame: Days 8-21
Area under the concentration-time curve in 1 dosing interval AUC (tau) for BMS-955176
Time frame: Days 8-21
Adverse events (AEs)
The incidence of observed AEs will be tabulated and reviewed for potential significance and clinical importance.
Time frame: Days 1-21; for SAEs up to 30 days post discontinuation of dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.